In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Statement from the ESC regarding the ENHANCE trial

Cardiovascular Pharmacology and Pharmacotherapy


Recent media reports have kindled a controversy over the effectiveness of the combination of ezetimibe with high dose simvastatin, versus the use of simvastatin alone, in patients with familial hypercholesterolemia.

The European Society of Cardiology urges patients not to take any decisions without discussing their particular case beforehand with their physician. Patients with high cholesterol levels should not stop taking their prescribed medication.

The ENHANCE (Effects of Combination Ezetimibe and High-Dose Simvastatin versus Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) trial is only one of the ongoing studies on the use of ezetimibe. The subject is being considered for discussion in our upcoming Congress and will be addressed in our peer reviewed journals.